- Conditions
- White Matter Injury, Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia, Periventricular White Matter Abnormalities
- Interventions
- Clemastine fumarate
- Drug
- Lead sponsor
- Bridget LaMonica Ostrem, M.D., Ph.D.
- Other
- Eligibility
- 3 Weeks to 20 Weeks
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 242
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Irregular Sleep Wake Rhythm Disorder
- Interventions
- Non-interventional
- Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 6
- States / cities
- Costa Mesa, California • San Diego, California • Miami, Florida + 3 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Step Tracking, Water Tracking
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 30 Years to 59 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Dementia, Vascular, Stroke Sequelae
- Interventions
- Home telerehabilitation therapy
- Other
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal, Dementia, Mixed, Dementia Alzheimers, Alzheimer Disease, Dementia Severe
- Interventions
- ADRD-PC Program
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 884 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more
- Conditions
- Brain Metastases, Neurocognitive Deficit, White Matter Alterations, Radiation Exposure
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive, Parkinsonism Vascular, Multiple System Atrophy, Corticobasal Degeneration, Alzheimer Disease, Frontotemporal Dementia, Primary Progressive Aphasia, Vascular Dementia
- Interventions
- Palliative Care
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 105 Years
- Enrollment
- 783 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- San Francisco, California • Aurora, Colorado
- Conditions
- Inherited Metabolic Disorders (IMD)
- Interventions
- MGTA-456
- Drug
- Lead sponsor
- Magenta Therapeutics, Inc.
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Cincinnati, Ohio
- Conditions
- Neuromyelitis Optica, Myelitis, Transverse, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
- Interventions
- Mitoxantrone
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- Not listed
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 10
- States / cities
- Cullman, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more
- Conditions
- Cerebral Autosomal Dominant Ateriopathy With Subcortical Infarcts and Leukoencephalopathy
- Interventions
- Registry
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Dementia, Cognitive Impairment, Mild, Dementia, Vascular, Dementia, Mixed, Dementia With Lewy Bodies, Dementia Frontal, Dementia Moderate, Dementia of Alzheimer Type, Dementia, Mild
- Interventions
- Referral for Cognitive Stimulation Therapy, No change to Standard of Care
- Behavioral · Other
- Lead sponsor
- University of Massachusetts, Amherst
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Farmington, Connecticut • New Haven, Connecticut
- Conditions
- Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
- Interventions
- Rifaximin SSD 40 mg IR tablet, Placebo
- Drug
- Lead sponsor
- Jasmohan Bajaj
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
- Interventions
- CerefolinNAC®
- Other
- Lead sponsor
- Pamlab, Inc.
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Hickory, North Carolina
- Conditions
- Perinatal Stroke, Hypoxic-ischemic Encephalopathy, White Matter Injury
- Interventions
- Increased protein
- Dietary Supplement
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Days to 3 Weeks
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Depression
- Interventions
- Escitalopram, Magnetic Resonance Imaging
- Drug · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2019
- U.S. locations
- 2
- States / cities
- New York, New York • White Plains, New York
- Conditions
- Hypothyroidism
- Interventions
- Levothyroxine
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- NT-I7
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
- Interventions
- Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia, PreDiabetes
- Interventions
- Not listed
- Lead sponsor
- Marinella Temprosa
- Other
- Eligibility
- Not listed
- Enrollment
- 1,976 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Alhambra, California • San Diego, California + 21 more
- Conditions
- Krabbe Disease
- Interventions
- Not listed
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Metachromatic Leukodystrophy
- Interventions
- Enriched Hematopoetic Stem Cell Infusion
- Biological
- Lead sponsor
- Talaris Therapeutics Inc.
- Industry
- Eligibility
- 3 Years and older · Male only
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alexander Disease
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation
- Interventions
- Zolpidem CR, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts